Business Description
Biogened SA
NAICS : 325412
SIC : 2834
ISIN : PLBIOGN00018
Compare
Compare
Traded in other countries / regions
BGD.Poland IPO Date
2011-08-31Description
Biogened SA is a Polish cosmetic company. The company defined its key areas of activity, concentrated its efforts on the development of neurological and psychiatric products. It also develops, produces and distributes ingredients, safe and effective dermo cosmetics under the Dermedic brand.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.26 | |||||
| Equity-to-Asset | 0.45 | |||||
| Debt-to-Equity | 0.59 | |||||
| Debt-to-EBITDA | 1.82 | |||||
| Interest Coverage | 3.74 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 2.65 | |||||
| Beneish M-Score | -2.59 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 25.5 | |||||
| 3-Year EBITDA Growth Rate | 19.2 | |||||
| 3-Year EPS without NRI Growth Rate | 92.5 | |||||
| 3-Year FCF Growth Rate | 3.9 | |||||
| 3-Year Book Growth Rate | 8.8 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 65.74 | |||||
| 9-Day RSI | 42.94 | |||||
| 14-Day RSI | 37.34 | |||||
| 6-1 Month Momentum % | 2.8 | |||||
| 12-1 Month Momentum % | 22.22 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.25 | |||||
| Quick Ratio | 1.19 | |||||
| Cash Ratio | 0.26 | |||||
| Days Inventory | 224.45 | |||||
| Days Sales Outstanding | 63.21 | |||||
| Days Payable | 145.82 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.5 | |||||
| Dividend Payout Ratio | 0.28 | |||||
| 3-Year Dividend Growth Rate | 26 | |||||
| Forward Dividend Yield % | 2.5 | |||||
| 5-Year Yield-on-Cost % | 2.5 | |||||
| Shareholder Yield % | -0.65 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 70.46 | |||||
| Operating Margin % | 7.88 | |||||
| Net Margin % | 4.54 | |||||
| FCF Margin % | -1.32 | |||||
| ROE % | 12.9 | |||||
| ROA % | 5.84 | |||||
| ROIC % | 9.76 | |||||
| ROC (Joel Greenblatt) % | 20.41 | |||||
| ROCE % | 16.94 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 10.08 | |||||
| PE Ratio without NRI | 11.33 | |||||
| Shiller PE Ratio | 15.69 | |||||
| PEG Ratio | 0.92 | |||||
| PS Ratio | 0.46 | |||||
| PB Ratio | 1.25 | |||||
| Price-to-Tangible-Book | 1.27 | |||||
| Price-to-Operating-Cash-Flow | 10.49 | |||||
| EV-to-EBIT | 7.52 | |||||
| EV-to-EBITDA | 5.17 | |||||
| EV-to-Revenue | 0.62 | |||||
| EV-to-FCF | -46.96 | |||||
| Price-to-Projected-FCF | 0.72 | |||||
| Price-to-Median-PS-Value | 0.73 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.62 | |||||
| Price-to-Graham-Number | 0.8 | |||||
| Price-to-Net-Current-Asset-Value | 9.8 | |||||
| Earnings Yield (Greenblatt) % | 13.3 | |||||
| FCF Yield % | -2.87 | |||||
| Forward Rate of Return (Yacktman) % | 22.61 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Biogened SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil zł) | 107.217 | ||
| EPS (TTM) (zł) | 1.984 | ||
| Beta | -0.09 | ||
| Volatility % | 68.09 | ||
| 14-Day RSI | 37.34 | ||
| 14-Day ATR (zł) | 0.199945 | ||
| 20-Day SMA (zł) | 19.685 | ||
| 12-1 Month Momentum % | 22.22 | ||
| 52-Week Range (zł) | 16.2 - 32.6 | ||
| Shares Outstanding (Mil) | 2.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biogened SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biogened SA Stock Events
| Event | Date | Price(zł) | ||
|---|---|---|---|---|
| No Event Data | ||||
Biogened SA Frequently Asked Questions
What is Biogened SA(WAR:BGD)'s stock price today?
The current price of WAR:BGD is zł20.00. The 52 week high of WAR:BGD is zł32.60 and 52 week low is zł16.20.
When is next earnings date of Biogened SA(WAR:BGD)?
The next earnings date of Biogened SA(WAR:BGD) is .
Does Biogened SA(WAR:BGD) pay dividends? If so, how much?
The Dividend Yield %  of Biogened SA(WAR:BGD) is 2.5% (As of Today), Highest Dividend Payout Ratio of Biogened SA(WAR:BGD) was 0.79. The lowest was 0.22. And the median was 0.4. The  Forward Dividend Yield % of Biogened SA(WAR:BGD) is 2.5%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers